吉西他滨联合白蛋白结合型紫杉醇经导管动脉灌注治疗晚期胰腺癌的疗效及安全性
Efficacy and safety of transcatheter arterial infusion chemotherapy with gemcitabine and nab-paclitaxel regimen for advanced pancreatic cancer
章浙伟 1曾晖 1郑家平 1罗君 1郭立文 1曹非 1梁维仁 1邵国良1
作者信息
- 1. 310022 浙江杭州 浙江省肿瘤医院介入治疗科;中国科学院杭州医学研究所
- 折叠
摘要
目的 评价吉西他滨联合白蛋白结合型紫杉醇(GN)经导管动脉灌注治疗晚期胰腺癌的疗效及安全性.方法 收集浙江省肿瘤医院2016年1月至2020年12月采用GN方案经导管动脉灌注治疗晚期胰腺癌患者50例,分析其客观有效率(ORR),无进展生存期(PFS),总生存期(OS)及治疗相关的毒性反应.结果 50例胰腺癌患者共行动脉灌注化疗236次,平均灌注4.72次,其中完全缓解(CR)0例,部分缓解(PR)16例,疾病稳定(SD)21例,ORR为32％,中位PFS为5.1个月,OS为9.8个月,不良事件主要包括中性粒细胞减少、血小板减少、呕吐、恶心和乏力等.结论 采用GN方案经导管动脉灌注治疗晚期胰腺癌有较好的近期疗效,且安全,可一定程度提升患者的PFS和OS.
Abstract
Objective To evaluate the clinical efficacy and safety of transcatheter arterial infusion with gemcitabine and nab-paclitaxel(GN)as first-line therapy in treating patients with advanced pancreatic cancer.Methods The clinical data of a total of 50 patients with advanced pancreatic cancer,who were treated with transcatheter arterial infusion chemotherapy with GN regimen at the Zhejiang Cancer Hospital of China between January 2016 and December2020,were collected The objective effective rate(ORR),progression-free survival(PFS),overall survival(OS)and treatment-related toxic reactions were analyzed.Results A total of 236 times of transcatheter arterial infusion chemotherapy were carried out in the 50 patients,with an average perfusion procedure of 4.72 times per patient.Complete remission(CR)was obtained in 0 patient,partial remission(PR)in 16 patients,and stable disease(SD)in 21 patients.The ORR was 32％,the median PFSwas5.1 months,and the OS was 9.8 months.The main adverse events included neutropenia,thrombocytopenia,vomiting,nausea,fatigue,etc.Conclusion For patients with advanced pancreatic cancer,transcatheter arterial infusion chemotherapy with GN regimen carries good short-term efficacy and safety,it can improve patient's PFS and OS to a certain extent.(J Intervent Radiol,2024,33:512-515)
关键词
吉西他滨/白蛋白结合型紫杉醇/动脉灌注化疗/晚期胰腺癌Key words
gemcitabine/nab-paclitaxel/arterial infusion chemotherapy/advanced pancreatic cancer引用本文复制引用
基金项目
浙江省卫生健康科技计划(2022KY687)
北京医学奖励基金会项目(YXJL-2020-1037-0549)
出版年
2024
NETL
NSTL
万方数据